Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 immunobridging study of single-dose RSVPreF3 OA vaccine in adults aged 60 years and older in China
CTR20243122Phase 3Completed
- Sponsor
- GSK
- Start
- Aug 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of GSK3003899A in respiratory syncytial virus disease (RSV), respiratory syncytial virus lower respiratory tract infection, sponsored by GSK. Started Aug 2024; status: completed.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus disease (RSV)respiratory syncytial virus lower respiratory tract infection
Beyond the preview
Go deeper on CTR20243122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243122.